Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
Open Access
- 1 July 2012
- journal article
- review article
- Published by Informa UK Limited in Clinical Ophthalmology
- Vol. 6, 1175-1186
- https://doi.org/10.2147/OPTH.S33372
Abstract
Abstract: Age-related macular degeneration (AMD) has become a major public health problem and a leading cause of blindness in industrialized nations. AMD results from the ageing eye's inability to metabolize and dispose completely of photoreceptor outer segments and other waste products. As a result, lipids, particularly apolipoproteins, accumulate within Bruch's membrane, leading to chronic ischemia and inflammation. The subsequent upregulation of inflammatory cytokines and growth factors, including vascular endothelial growth factor (VEGF), induces the growth of neovascular membranes from the choriocapillaris into the subretinal or subretinal pigment epithelium spaces. To counter this, intravitreally administered drugs (pegaptanib, bevacizumab, ranibizumab) that specifically target VEGF have become the standard treatment for exudative AMD. Aflibercept, a recently approved fusion protein, binds to all isoforms of both VEGF-A and placental growth factor with high affinity. Phase III trials showed that monthly or every other month injections of aflibercept prevent vision loss (fewer than 15 letters) in 95% of patients. Additionally, aflibercept injections every 4 or 8 weeks produce average vision gains of 6.9 letters to 10.9 letters, comparable with those achieved with monthly ranibizumab. After one year of regularly administered aflibercept injections, patients required an average of only 4.2 injections during the second year. Aflibercept promises to decrease the injection frequency required for many patients and appears to serve as an effective “salvage” therapy for patients who respond poorly to other anti-VEGF drugs.Keywords
This publication has 106 references indexed in Scilit:
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- A Subretinal Matrigel Rat Choroidal Neovascularization (CNV) Model and Inhibition of CNV and Associated Inflammation and Fibrosis by VEGF TrapInvestigative Ophthalmology & Visual Science, 2010
- Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomesProceedings of the National Academy of Sciences of the United States of America, 2008
- ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein responseBlood, 2008
- Age-related changes in human macular Bruch's membrane as seen by quick-freeze/deep-etchExperimental Eye Research, 2007
- Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cellsExperimental Eye Research, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003
- Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degenerationAmerican Journal of Ophthalmology, 2002
- Novel mechanism for age‐related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDFJournal of Cellular Physiology, 2001